Scilex Holding Company Royalty Expense
Scilex Holding Company (SCLX) reported Royalty Expense of $0 for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-14.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:RoyaltyExpense · last filed 2026-08-14
- Scilex Holding Company royalty expense for the quarter ending 2026-06-30 was $0.00, a 100.00% decline year-over-year.
- Scilex Holding Company royalty expense for the quarter ending 2026-03-31 was $0.00, a 100.00% decline year-over-year.
- Scilex Holding Company royalty expense for the quarter ending 2025-12-31 was $0.00, a 100.00% decline year-over-year.
- Scilex Holding Company royalty expense for the quarter ending 2025-09-30 was $100.00K, a 0.00% change year-over-year.
- Scilex Holding Company royalty expense for fiscal 2025 was $200.00K, a 33.33% decline from fiscal 2024.
- Scilex Holding Company royalty expense for fiscal 2024 was $300.00K, a 1053.85% increase from fiscal 2023.
- Scilex Holding Company royalty expense for fiscal 2023 was $26.00K.
| Period end | Royalty Expense 3 month | Royalty Expense 6 month | Royalty Expense 9 month | Royalty Expense 12 month |
|---|---|---|---|---|
| 2026-06-30 | $0.00 10-Q · filed 2026-08-14 | $0.00 10-Q · filed 2026-08-14 | $0.00 derived: sum of 3 quarters · filed 2026-08-14 | $100.00K derived: sum of 4 quarters · filed 2026-08-14 |
| 2026-03-31 | $0.00 10-Q · filed 2026-05-20 | $0.00 derived: sum of 2 quarters · filed 2026-05-20 | $100.00K derived: sum of 3 quarters · filed 2026-05-20 | $200.00K derived: sum of 4 quarters · filed 2026-08-14 |
| 2025-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-04-10 | $100.00K derived: sum of 2 quarters · filed 2026-04-10 | $200.00K derived: sum of 3 quarters · filed 2026-08-14 | $200.00K 10-K · filed 2026-04-10 |
| 2025-09-30 | $100.00K 10-Q · filed 2025-11-14 | $200.00K derived: sum of 2 quarters · filed 2026-08-14 | $200.00K 10-Q · filed 2025-11-14 | $500.00K derived: sum of 4 quarters · filed 2026-08-14 |
| 2025-06-30 | $100.00K 10-Q · filed 2026-08-14 | $100.00K 10-Q · filed 2026-08-14 | $400.00K derived: sum of 3 quarters · filed 2026-08-14 | $500.00K derived: sum of 4 quarters · filed 2026-08-14 |
| 2025-03-31 | $100.00K 10-Q · filed 2026-05-20 | $300.00K derived: sum of 2 quarters · filed 2026-05-20 | $400.00K derived: sum of 3 quarters · filed 2026-05-20 | $500.00K derived: sum of 4 quarters · filed 2026-05-20 |
| 2024-12-31 | $200.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-04-10 | $300.00K derived: sum of 2 quarters · filed 2026-04-10 | $400.00K derived: sum of 3 quarters · filed 2026-04-10 | $300.00K 10-K · filed 2026-04-10 |
| 2024-09-30 | $100.00K 10-Q · filed 2025-11-14 | $200.00K derived: sum of 2 quarters · filed 2025-11-14 | $100.00K 10-Q · filed 2025-11-14 | |
| 2024-06-30 | $100.00K 10-Q · filed 2025-08-13 | $100.00K 10-Q · filed 2025-08-13 | ||
| 2024-03-31 | $0.00 10-Q · filed 2025-05-14 | |||
| 2023-12-31 | $26.00K 10-K · filed 2025-03-31 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Metagenomi Therapeutics, Inc. (MGX) | United States | $0.044B | -0.48 |
| LeonaBio, Inc. (LONA) | United States | $0.047B | -0.61 |
| Instil Bio, Inc. (TIL) | United States | $0.048B | -1.73 |
| Tevogen Inc. (TVGN) | United States | $0.049B | |
| aTYR PHARMA INC (ATYR) | United States | $0.033B | -0.98 |
| Quince Therapeutics, Inc. (QNCX) | United States | $0.031B | |
| CEL SCI CORP (CVM) | United States | $0.030B | -0.81 |
| Inmune Bio, Inc. (INMB) | United States | $0.056B | -2.48 |
| ImageneBio, Inc. (IMA) | United States | $0.056B | -1.31 |
| BioAtla, Inc. (BCAB) | United States | $0.058B | -0.21 |